Effect of Serum Vitamin D Level on the Efficacy of Peg-interferon Treatment in CHB
Chronic Hepatitis b
About this trial
This is an interventional treatment trial for Chronic Hepatitis b focused on measuring hepatitis B, Vitamin D, Interferon
Eligibility Criteria
Inclusion Criteria: 1.According with the diagnosis of chronic hepatitis B in the guideline of China in 2015 2.18-60 years old 3.More than 1 year history of nucleot(s)ide analogues therapy with HBsAg ≤1500 IU/ml, negative HBeAg and HBV DNA<100 IU/ml 4.No contraindications of interferon Exclusion Criteria: Allergy to interferon Alanine transaminase >10 times of upper limit of normal(ULN) or total bilirubin >2 times of ULN existing or previous decompensated liver cirrhosis White blood cells or Platelet below the lower limit of normal existing severe organ injury combined with autoimmune diseases, psychiatric diseases, diabetes or thyroidism confirmed or suspected malignant tumors before or after transplantation using immunosuppressor pregnant or having a planned parenthood in 2 years alcohol or drug addicted infected by HIV any conditions that is unsuitable to interferon therapy according to the doctors' judgement
Sites / Locations
- Department of Infectious Diseases, The Third Affliated Hospital of Sun Yat-sen University
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
treatment group
control group
pegylated interferon 180ug/week and oral vitamin D3 800IU/day for no longer than 48 weeks
pegylated interferon 180ug/week for no longer than 48 weeks